The sexist behaviour of immune checkpoint inhibitors in cancer therapy? - Wikidata - awgldk - TriplyDB

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

http://www.wikidata.org/entity/Q47138418

about

Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

P2860

Q52606149-67629C53-137E-49ED-8EE9-7839ADEC8BBE Q58705140-87961440-A8EC-4288-84F8-DC70FFD12D58 Q58754581-D4CCB5A7-1781-4796-9BDD-19561F2C5B56

P2860

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

http://www.wikidata.org/entity/Q47138418

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

@en

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

@nl

type

label

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

@en

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

@nl

prefLabel

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

@en

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

@nl

P1433

Q47138418-CC62D250-C383-4299-BF71-EBA408A37B8F

P1476

Q47138418-CC4563ED-53B4-4811-886B-9B983DC36A17

P2093

Q47138418-18FBA2E6-023E-4D3F-B705-A69E378332F8

Q47138418-3AE9CA65-0578-404A-94C9-CF592AA287F3

Q47138418-478D9A79-7803-40C6-87A3-9416AEC77355

Q47138418-54657276-E3F3-4C78-9F81-0A48E2AFFEA3

Q47138418-561542A3-EA81-4CF3-893C-F186A04CC680

Q47138418-6F31E5E5-3E15-4505-BA8B-B321DF0DC164

Q47138418-71CDE6AC-B4E9-4AFA-BFB8-2482FF5A14AA

Q47138418-72046AF0-8829-47DB-AA13-28A999570985

Q47138418-AE03F7E9-9710-4977-A73D-10404C747224

Q47138418-CB7184AD-F770-4B22-A123-76E36162B1B9

P2860

Q47138418-00F98ACA-9DEF-4CCB-9B11-F806A4948E78

Q47138418-0699C2D6-4E02-48DB-9C26-390DC96782D0

Q47138418-12E89C61-288A-4A66-8756-37F1DBFB7FBD

Q47138418-133A2D30-1F45-4CD5-ABD2-81D0FE57C9BB

Q47138418-13C610C4-B01A-4AC8-A63D-514BAB07CC03

Q47138418-19D8C8E5-E04E-432B-BB91-8D04D6921DCA

Q47138418-1BD9548D-5B62-47A8-880D-97FBEA4CE6AD

Q47138418-1EC4D06A-B6E0-4F5E-92E8-8670055DB957

Q47138418-2211B0C6-F2A9-40A6-B4B0-84D5371FDAC8

Q47138418-27AE850C-EEF1-4A03-8CAB-C5DA16E14B5F

P304

Q47138418-B0D38769-2A41-4527-BBBB-4F41212E602D

P31

Q47138418-FE96117B-CE70-4E8C-ABA0-8721C5966A56

P356

Q47138418-9F60A886-311E-497D-87C5-5C50F860A169

P407

Q47138418-584E5D14-EB50-4AF7-99AF-A97F768A9AC6

P433

Q47138418-2AA45AD6-4493-4FEB-8012-8D8782FA56CE

P478

Q47138418-B337490F-285F-4E6E-A023-6C9133AADB54

P50

Q47138418-1484D18D-0B4D-475F-B858-75632BAFAE9E

Q47138418-394B5D25-A859-4AC4-8258-FABBB9155E31

Q47138418-BFE898E6-1C96-4B52-AFA5-CB2B24FE33C9

Q47138418-E2A67026-349E-4BCD-8DE3-B29B886CFF5D

P577

Q47138418-D7BB9163-802E-4DC6-B7E7-FE72D88BC58E

P698

Q47138418-FEF37DC3-110E-4443-B001-C45BF01AED86

P932

Q47138418-7E0D2C01-1C09-4B58-8090-D5C3767C9245

P356

ONCOTARGET.22242

P1433

P1476

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

@en

P2093

Adriana Bonifacino

http://www.w3.org/2001/XMLSchema#string

Bruna Cerbelli

http://www.w3.org/2001/XMLSchema#string

Chiara Napoletano

http://www.w3.org/2001/XMLSchema#string

Concetta Elisa Onesti

http://www.w3.org/2001/XMLSchema#string

Federica Mazzuca

http://www.w3.org/2001/XMLSchema#string

Francesca Di Pietro

http://www.w3.org/2001/XMLSchema#string

Giulia D'Amati

http://www.w3.org/2001/XMLSchema#string

Ilaria Zizzari

http://www.w3.org/2001/XMLSchema#string

Laura Pizzuti

http://www.w3.org/2001/XMLSchema#string

Lidia Strigari

http://www.w3.org/2001/XMLSchema#string

P2860

Stenting versus endarterectomy for treatment of carotid-artery stenosis.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

Immune checkpoint blockade: a common denominator approach to cancer therapy

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Tumor Immunotherapy Directed at PD-1

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

P304

99336-99346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22242

http://www.w3.org/2001/XMLSchema#string

P407

P433

59

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Marchetti

Andrea Botticelli

Mario Occhipinti

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29245905

http://www.w3.org/2001/XMLSchema#string

P932

5725096

http://www.w3.org/2001/XMLSchema#string